Selection Criteria in Colorectal Cancer Screening

Hemoccult Sensitivity Estimate in a Screening Program for Colorectal Cancer in the Province of Florence

The sensitivity of Hemoccult testing (HO) in a population-based screening for colorectal cancer was evaluated. HO sensitivity estimates were calculated as the ratio of screen-detected HO-positives to total screen or interval-detected cancers. Sensitivity was estimated according to 1, 2, and 3-year rescreening intervals. Corresponding estimates are 69.4%, 61.8% and 57.7%, respectively. No significant correlation was observed between HO sensitivity and other variables, such as calendar period, tumor stage or site, or patient age or sex. HO sensitivity as estimated in the present experience is consistent with other reports of population-based screenings. Screening every year would achieve too limited an increase in sensitivity, compared to biennal screening, to be worth the difficulties of doubling organizational efforts and costs.

Early detection for colorectal cancer: new aspects in fecal occult blood screening

The authors report on promising diagnostic methods of occult intestinal bleeding and discusses the potential new strategy of early detection of colorectal carcinomas in respect to old and new diagnostic measures available. Because of the limited sensitivity and specificity of classical methods used for the demonstration of occult fecal blood, the authors recommend the introduction of new techniques and markers in screening practice. It is presumed that new discoveries in molecular biology will improve the accuracy of early colorectal cancer prevention. Their implementation into routine screening, however, will not take place in the near future. Until their realization, improved screening efficacy is expected from the use of more specific and sensitive blood tests.

Filtering strategies in mass population screening for colorectal cancer: an economic evaluation

On the basis of clinical trial data, 13 strategies for initial screening (filtering) for colorectal cancer are modeled for the purpose of economic evaluation. A wide range of detection cost estimates are generated, although ranking options by detection cost ignores the important consideration of undetected cancers. Formulating the problem as one of cost-effectiveness, however, allows the authors to demonstrate that members of a subset of strategies uniquely outperform all others and that the optimum strategy can be identified by the ex ante specification of the valuation of cancers missed on screening.